Ridinilazole—a novel antibiotic for treatment of Clostridium difficile infection

Clostridium difficile (C. difficile) infection has become a major health problem worldwide and is considered to be one of the most common hospital-acquired (nosocomial) infections with increasing incidence and severity (1). In Germany, the number of C. difficile infections (CDI) increased from 7 to 39 reported cases per 100,000 hospitalized patients between 2000 and 2004, with yet another doubling of numbers between 2004 and 2006 (2).